Journal of Liver: Disease & TransplantationISSN: 2325-9612

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Analysis of Pretreatment Predictors of a Virological Response to Interferon Therapy in Co-infected Patients of Hepatitis C and B

Background: Several pretreatment parameters are strongly associated with sustained virological response rate (SVR) in HCV/ HBV co-infected patients.

Methods: We identified 104 HCV/HBV co-infected patients (69 males and 35 females) who were treated with standard interferon-alfa-2a or pegylated-IFN-alfa-2b by using electronic query. Data analysis includes their age, gender, clinical, hierological and histological parameters.Patients were divided into two groups of interferon responders (negative HCV RNA level) and non-responders (patients with positive HCV-RNA levels). Multivariate regression analysis was used to assess the effect of pre-treatment variables and therapy regime on sustained virological rate (SVR) in both groups.

Results: The pretreatment parameters significantly associated with sustained virological response to interferon therapy were low levels of serum ALT (p=0.002), HCV-RNA (Ë‚4×105 IU/ml) (p=0.038), HBVDNA(Ë‚2×104 IU/ml) (p=0.002), HCV genotype-3 (p=0.025) and IL- 28B CC genotype (p=0.049). As for histological factors, normal to minimal change in liver biopsy was found considerably associated with therapy response (p=0.024). Significant advantage of peginterferon plus ribavirin was also observed for SVR (p=0.004).Post-treatment HBV-DNA clearance was observed in 22% of 104 co-infected patients.

Conclusion: Pretreatment parameters are closely related with better response to therapy. Peg-interferon and ribavirin in combination is an effective regime significantly associated with SVR in HCV/HBV co-infected patients.

 

Special Features

Full Text

View

Track Your Manuscript

Media Partners

GET THE APP